High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors

Table 2

Factors predictive of high-dose toremifene therapeutic efficacy.

			ORR			CBR
				%	value		%	value
Total		19	4	21.1		6	31.6
HER2	Positive	4	1	25.0	1.000	1	25.0	1.000
	Negative	15	3	20.0		5	33.3
History of tamoxifen	Yes	4	1	25.0	1.000	2	50.0	0.557
	No	15	3	20.0		4	26.7
History of AI	Yes	17	2	11.8	0.035	4	23.5	0.088
	No	2	2	100.0		2	100.0
Liver metastasis	Yes	7	0	0.0	0.245	0	0.0	0.044
	No	12	4	33.3		6	50.0
Lung metastasis	Yes	12	2	16.7	0.603	3	25.0	0.617
	No	7	2	28.6		3	42.9
Bone metastasis	Yes	11	1	9.1	0.134	2	18.2	0.141
	No	8	3	37.5		4	50.0
Visceral metastasis	Yes	14	2	14.3	0.272	3	21.4	0.262
	No	5	2	40.0		3	60.0
AI resistance	Primary	9	0	0.0	0.087	1	11.1	0.294
	Secondary	8	2	25.0		3	37.5

ORR: overall response rate; CBR: clinical benefit rate; HER2: human epidermal growth factor receptor 2; AI: aromatase inhibitor.